

## **Leukocare and Formycon cooperate in the development of high-quality biopharmaceuticals**

- **Companies combine leading development expertise in high-quality biopharmaceuticals with profound knowhow in biopharmaceutical formulation development**
- **Master Service Agreement stipulates potential development of stable Leukocare formulations for additional Formycon projects in upcoming years**
- **First project covers formulation development for a biosimilar of a blockbuster therapeutic antibody**

Martinsried/Munich, March 24, 2021

Leukocare AG and Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced a collaboration in the area of high-quality biopharmaceuticals. Under the terms of this agreement, Leukocare will apply its formulation development technologies combining state-of-the-art protein analytics, bioinformatics and artificial intelligence to develop stable formulations potentially for several candidates in Formycon's product pipeline. The first project has been started and covers the formulation development for a biosimilar of a blockbuster therapeutic antibody.

By applying Leukocare's formulation and bioinformatics expertise to Formycon's comprehensive development knowhow, the partners want to achieve superior stability profiles overall leading to additional value propositions for development projects.

Michael Scholl, Chief Executive Officer at Leukocare, commented, "We are very proud of this partnership with Formycon, a world-leading developer of high-quality biosimilars and biopharmaceuticals. This collaboration is a perfect fit for both companies to drive the development of high-quality products."

Andreas Seidl, Chief Operating Officer of Leukocare, added, "Our algorithm-based formulation development expertise will allow Formycon to make use of a large formulation design space,

thereby gaining manifold options for freedom to operate in a competitive environment. This will strongly support Formycon in providing high-quality medicines to as many patients as possible.”

Stefan Glombitza, Chief Operating Officer at Formycon, stated, “Suitable Drug Product formulations are an essential success factor in the development of biopharmaceutical drugs and are getting increasingly important in the competitive IP landscape. We are convinced that Leukocare's technology platform can successfully complement our development expertise and look very much forward to our collaboration.”

### **About Leukocare AG**

Leukocare AG, located in Martinsried/Munich, Germany, is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence.

The formulation development approach consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and a rational development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product's needs. Leukocare's superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

[www.leukocare.com](http://www.leukocare.com)

### **About Formycon AG**

Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 fusion protein.

**Contact:**

**Leukocare**

Dr. Andreas Seidl

COO

[andreas.seidl@leukocare.com](mailto:andreas.seidl@leukocare.com)

+ 49 (0) 89 7801 6650

Rebekka Ströver

Specialist Communications & Marketing

[rebekka.stroever@leukocare.com](mailto:rebekka.stroever@leukocare.com)

+ 49 (0) 89 7801 665 14

**Formycon AG**

Sabrina Müller

Senior Manager Corporate Communications  
and Investor Relations

Fraunhoferstr. 15

82152 Martinsried/Planegg/Germany

Phone.: +49 (0) 89 - 86 46 67 149

Fax + 49 (0) 89 - 86 46 67 110

[Sabrina.Mueller@formycon.com](mailto:Sabrina.Mueller@formycon.com)

[www.formycon.com](http://www.formycon.com)